Sign inJoin
Company / Finance

Adial Pharmaceuticals, Inc.

ADIL · NASDAQ

ADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.

FollowAdd to WatchlistAsk Question
NASDAQADILCoverage BootstrapBiotechnologyAddiction MedicineAlcohol Use Disorder
Latest ReportMay 14, 2026Adial Pharmaceuticals: the cheek-swab alcohol-use pill racing a 2026 runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 of 1 reports match
Clear filters
Selected tags
Biotechnology
Clear tags
Latest Thesis

Adial Pharmaceuticals: the cheek-swab alcohol-use pill racing a 2026 runway

ADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.

May 14, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Adial Pharmaceuticals, Inc.Pharmaceuticals: the cheek-swab alcohol-use pill racing a 2026 rMay 14, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Adial Pharmaceuticals: the cheek-swab alcohol-use pill racing a 2026 runwayADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.NASDAQMay 14, 2026Research reportReadSlides